Pan European M&A at record levels in 2018

HBM Pharma/Biotech M&A Report 2018

Analysis of Biopharma M&A in 2018 (and previous years)

Key Findings

  • Worldwide biopharma M&A volume of completed deals (including the $59 billion Shire/Takeda deal1) reached $149.3 billion in 2018 (up from $75.9 billion in 2017). These numbers include contingent payments and as well as asset deals and sale of business units.
  • Besides the widely commented Shire/Takeda deal, there were only two further transactions over $10 billion: GlaxoSmithKline bought out Novartis’ stake in their consumer health joint venture for $13 billion and Sanofi acquired US-listed hemophilia company Bioverativ for $11.6 billion.
  • US deal volume (based on location of target company/business) in 2018 rose to $48.7 billion (up from around $30 billion in 2017).
  • In Europe the Shire/Takeda deal lifted deal volume to $97.3 billion, a number that is roughly twice as high as in 2017.
  • Average premiums paid for public biopharma companies rose to over 70%.
  • As in the years 2016 and 2017, M&A transaction volume outside of the US and Europe was modest in 2018 with a total deal value of only $3.3 billion.
  • Private deal making in 2018 was dominated by trade sales of innovation-driven and VC backed companies, both in the US and in Europe.
  • Return multiples to VC investors from M&A stayed at very high levels in 2018 with average multiples on upfront proceeds alone now surpassing 5x.

———————————————————————————————————————————————————————————————————

Will this trend continue in 2019?

  • It is interesting to note that the valuation of assets in the EU remain lower then US.
  • We envisage that the IPO environment is going to be less favourable in the near future, which will be cushioned by increased VC liquidity. 
  • The dynamics around VC performance are changing with faster earn-back periods, and a larger portion financed by pharma-dollars.

Optimum’s Anne Marieke Ezendam will be reviewing these trends in a separate article. Please do visit our Insights for this piece in the coming weeks.

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH